Catalyst
Slingshot members are tracking this event:
Pre-NDA Discussion with FDA for MP-376 in Cystic Fibrosis Scheduled for 2Q 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RPTP |
|
|
||||
Additional Information
- Raptor had a meeting with the FDA in the second quarter concerning MP-376 for the management of chronic pulmonary infections due toPseudomonas aeruginosa in adult patients with cystic fibrosis in the U.S. The FDA requested additional information pertinent to Raptor's existing trials prior to the company's potential submission of an NDA. Raptor submitted a response to the FDA's request and expects to have additional discussions with the FDA.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 19, 2016
Occurred Source:
http://ir.raptorpharma.com/releasedetail.cfm?ReleaseID=983090
Related Projects
Related Keywords
Pre-nda Discussion, Fda, Cystic Fibrosis, Mp-376
